The Brain Institute of America

The Brain Institute of America is a biomedical research company based in New Haven, Connecticut, in the United States. According to its official website, the Institute was formed in 2017 with the goal of developing biomarkers for a variety of neurological disorders and malignancies of the central nervous system. Its stated mission is to develop effective RNA-based biomarkers for these disorders, with a specific focus on non-coding RNAs — a class of biomolecules that operate by controlling the abundance of a genetic element and are sometimes described as the "dark matter of the genome" because their functions were long poorly understood. The Institute's research centers on non-coding RNAs that are highly expressed in brain tissue, which it is pursuing for biomarker development. Its work is motivated by the view that non-coding RNA genes, linked within the past decade to a number of diseases, could help explain the nature of central nervous system tumors including glioblastoma multiforme. The company notes that glioblastoma multiforme and various neurological disorders are debilitating diseases associated with socio-economic hardship and emotional trauma for patients' family members and friends who care for them. Operationally, The Brain Institute of America describes itself as operating in New Haven, CT with access to state-of-the-art equipment and facilities. It states that it is in Phase I development, geared toward developing biomarkers for clinical use; in Phase II, curated biomarkers are intended to be commercialized into a product for clinical testing and use. Beyond its internal research programs, the Institute offers non-coding RNA consulting services, with rates determined on a per-customer basis. The organization is a small, privately held research enterprise rather than a publicly listed company, and no parent company, founder, or executive leadership is identified in the available public materials. Its public communications emphasize its mission, technology, and current initiatives, including RNA-focused programs. As a research-stage company, its near-term value proposition rests on the scientific promise of RNA-based biomarkers rather than on marketed products.

The Brain Institute of America was formed in 2017, according to its official website, with the goal of developing biomarkers for a variety of neurological disorders and malignancies of the central nervous system. From its base in New Haven, Connecticut, the Institute set out to focus specifically on non-coding RNAs — genetic elements often described as the "dark matter of the genome" because so little was known about their function. The Institute's rationale is that non-coding RNA genes, linked within the past decade to a number of diseases, remain an unexplored resource of genetic information that could help explain the nature of central nervous system tumors including glioblastoma multiforme. The Institute's stated mission is to develop effective RNA-based biomarkers for neurological disorders and CNS malignancies. It reports that several non-coding RNAs found to be highly expressed in brain tissue are currently being pursued for biomarker development. The organization describes itself as a biomedical research company operating in New Haven, CT with access to state-of-the-art equipment and facilities. In terms of development stage, the Institute states that it is currently in Phase I development, geared toward developing biomarkers for clinical use. In Phase II, curated biomarkers are intended to be commercialized into a product for clinical testing and use. Alongside its internal research, the Institute offers non-coding RNA consulting services, with rates determined on a per-customer basis. The available public record does not identify the Institute's founders, executive leadership, ownership structure, or any parent company, and it does not indicate that the company is publicly listed. Its public communications emphasize its mission, technology, and current initiatives, including RNA-focused programs. As of the available evidence, the Institute remains an active, research-stage enterprise whose progress is measured by the development of RNA-based biomarkers rather than by commercial product sales.

• 2017

  The Brain Institute of America is formed with the goal of developing biomarkers for neurological disorders and central nervous system malignancies.

• The Institute reports being in Phase I development, focused on developing biomarkers for clinical use.

• The Institute offers non-coding RNA consulting services with per-customer rates.

A research-stage biomedical company focused on non-coding RNA biomarkers for neurological disorders and central nervous system malignancies, operating from New Haven, Connecticut.

• Non-coding RNA consulting services

  Consulting services focused on non-coding RNA-based research, with rates determined on a per-customer basis.

• RNA-based biomarker development

  Development of non-coding RNA biomarkers for neurological disorders and CNS malignancies; Phase I focuses on clinical-use biomarkers, with Phase II intended to commercialize curated biomarkers.

1. 1The Brain Institute of Americabraininstituteamerica.com
2. 2About The Institute — The Brain Institute of Americabraininstituteamerica.com
3. 3Services — The Brain Institute of Americabraininstituteamerica.com
4. 4Non-coding RNA Consulting Services — The Brain Institute of Americabraininstituteamerica.com
5. 5The Brain Institute of America (United States) — Wikidatawikidata.org